Shared on20 Aug 25Fair value Decreased 7.14%
The consensus price target for BioGaia has been revised down to SEK130.00, primarily reflecting a decline in the company’s expected future P/E ratio. What's in the News BioGaia launched a subsidiary, BioGaia New Sciences AB, to develop microbiome-friendly products beyond gut, immune, and oral health, focusing first on skin health.
Shared on23 Apr 25Fair value Decreased 0.94%
AnalystConsensusTarget has decreased revenue growth from 11.3% to 9.7%.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Decreased 0.25%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on13 Mar 25Fair value Increased 5.93%
AnalystConsensusTarget has increased revenue growth from 10.2% to 11.3% and decreased discount rate from 5.3% to 4.8%.